In summary, IMDC risk, pathological features (sarcomatoid histology and tumor angiogenesis), and the TIME (status of pre-existing immunity, PD-L1 expression, and T-effector gene expression) are considered key factors in selecting 1L treatment for mRCC. The gene discussed is CD274; the disease is neoplasm.